ELI LILLY & Co (LLY)
ELI LILLY & Co (LLY) from its SEC filings: 2025 revenue $65.2 billion (+45% vs the year before), net margin 32%, free cash flow $16.8 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $65.2 billion |
| Revenue growth | +45% |
| Net income | $20.6 billion |
| Net margin | 31.7% |
| Free cash flow | $16.8 billion |
| Diluted EPS | $22.95 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +48% |
| Cash | $8.9 billion |
| Long-term debt | $47.9 billion |
| Share count, 1 year | -0% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.